Cumulative incidence of renal dysfunction in HIV-infected patients

<p>Cumulative incidence of renal dysfunction in HIV-infected patients</p

Diseases that were newly diagnosed or nephrotoxic drugs that were given in HIV-infected patients with normal renal function on tenofovir-based antiretroviral therapy between January 2012 and December 2013 in Myanmar.

<p>ART = antiretroviral therapy</p><p>^a included amphotericin B, amikacin, acyclovir, non-steroidal anti-inflammatory drugs</p><p>Diseases that were newly diagnosed or nephrotoxic drugs that were given in HIV-infected patients with normal renal function on tenofovir-based antiretroviral therapy between January 2012 and December 2013 in Myanmar.</p

Baseline characteristics of HIV-infected patients started on tenofovir-based antiretroviral therapy between January 2012 and December 2013 in Myanmar.

<p>BMI = body mass index; WHO = World Health Organization</p><p>^a Percentage of those tested</p><p>^b Creatinine clearance ≥ 50ml/min/1.73m²</p><p>^c Creatinine clearance < 50ml/min/1.73m²</p><p>Baseline characteristics of HIV-infected patients started on tenofovir-based antiretroviral therapy between January 2012 and December 2013 in Myanmar.</p

Management and results of the screening algorithm to determine antiretroviral therapy failure in HIV-infected patients, Mandalay, Myanmar.

<p>Management and results of the screening algorithm to determine antiretroviral therapy failure in HIV-infected patients, Mandalay, Myanmar.</p

Association between baseline characteristics and the development of antiretroviral therapy failure in HIV-infected patients starting stavudine-based or zidovudine-based antiretroviral therapy, Mandalay, Myanmar.

<p>Association between baseline characteristics and the development of antiretroviral therapy failure in HIV-infected patients starting stavudine-based or zidovudine-based antiretroviral therapy, Mandalay, Myanmar.</p

Baseline characteristics of previously-treated smear-positive TB patients, by DST status, registered under RNTCP in Gujarat, India, January-June 2013.

<p>Baseline characteristics of previously-treated smear-positive TB patients, by DST status, registered under RNTCP in Gujarat, India, January-June 2013.</p

Comparison of treatment outcomes across clinical and demographic factors of previously treated smear-positive TB patients registered in Gujarat from January-June 2013 (n = 5,829).

<p>Comparison of treatment outcomes across clinical and demographic factors of previously treated smear-positive TB patients registered in Gujarat from January-June 2013 (n = 5,829).</p

Treatment outcomes of previously-treated smear-positive TB patients, by DST status, registered under RNTCP in Gujarat, India, January-June 2013.

<p>Treatment outcomes of previously-treated smear-positive TB patients, by DST status, registered under RNTCP in Gujarat, India, January-June 2013.</p

Treatment outcomes of previously-treated smear-positive TB patients, by INH resistance, registered under RNTCP in Gujarat, India, January-June 2013 (N = 3743).

<p>Treatment outcomes of previously-treated smear-positive TB patients, by INH resistance, registered under RNTCP in Gujarat, India, January-June 2013 (N = 3743).</p

Distribution of SARS-CoV-2 seropositive of participants by site, round and age group (<18 years and ≥18 years).

Distribution of SARS-CoV-2 seropositive of participants by site, round and age group (<18 years and ≥18 years).</p